0
Articles |

Benefits of Neoadjuvant Chemotherapy in NSCLC FREE TO VIEW

Ugo Pastorino
Author and Funding Information

From the Royal Brompton Hospital, London, United Kingdom


1996 BY THE AMERICAN COLLEGE OF CHEST PHYSICIANS


Chest. 1996;109(5_Supplement):96S-101S. doi:10.1378/chest.109.5_Supplement.96S
Text Size: A A A
Published online

Abstract

There is a significant potential benefit for induction chemotherapy in the management of non-small cell lung cancer (NSCLC). The real extent of such benefit is difficult to assess on the basis of available data owing to the intrinsic limitations of phase II studies. In fact, in most studies on neoadjuvant chemotherapy, the aim of the treatment (local control vs systemic effect) is often unclear, the eligibility criteria poorly defined, and pretreatment staging inadequate. Consequently, the interpretation of the results of such studies has proved difficult. This article examines the critical role of thoracic surgeons in the selection, staging, and optimal treatment of patients enrolled in neoadjuvant studies, and also in monitoring the quality of data and providing adequate specimens for concurrent biologic research. Within the framework of controlled trials, with proper methods and minimum toxic reactions, induction chemotherapy may be offered in the future to a large number of patients and eventually combined with long-term adjuvant/chemopreventive strategies.


This article is only available in the PDF format. Download the PDF

Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

CHEST Journal Articles
CHEST Collections
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543